HSD3B1 and prostate carcinoma: The prostate cancer mortality data associated with HSD3B1 (16, 17), combined with the pharmacologic actionability inferred by this study, together suggest that HSD3B1 should also be interrogated in ongoing hormonal therapy studies in earlier disease states, including PROTEUS (NCT03767255), ENZARAD (NCT02446444), DASL-HiCaP (NCT0436353), NRG-GU008 (NCT04134260), NRG-GU009 (NCT04513717), and others.